» Articles » PMID: 15548564

Glomerular Podocytopathy in Patients with Systemic Lupus Erythematosus

Overview
Specialty Nephrology
Date 2004 Nov 19
PMID 15548564
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

A series of patients with systemic lupus erythematosus (SLE) and proteinuria were studied to determine whether nephrotic-range proteinuria was associated with diffuse epithelial cell foot process effacement in the absence of peripheral glomerular immune aggregate deposition. Biopsies from patients with known or suspected SLE and a histologic diagnosis of (1) normal by light microscopy, (2) mesangial proliferative glomerulonephritis, or (3) focal segmental glomerulosclerosis were studied. Biopsies were excluded when they demonstrated endocapillary proliferation or necrosis by light microscopy or electron-dense glomerular basement membrane deposits by electron microscopy. Patients were required to fulfill four of 11 American Rheumatologic Association criteria for the diagnosis of SLE, and proteinuria could not be associated with nonsteroidal anti-inflammatory drug use. Eighteen biopsies were studied, eight from patients with nephrotic-range proteinuria (>/=3 g/d) and 10 from patients with non-nephrotic proteinuria. The time from diagnosis of SLE to biopsy was shorter for nephrotic patients that for nonnephrotic patients. Seven of eight biopsies from nephrotic patients demonstrated at least 80% foot process effacement, whereas no biopsy from a nonnephrotic patient exhibited >20% effacement. There were no other significant pathologic differences between the nephrotic and nonnephrotic patients. The single common morphologic feature associated with nephrotic proteinuria was diffuse visceral epithelial cell foot process effacement. It is concluded that the development of nephrotic-range proteinuria in patients with SLE without peripheral immune aggregate deposition or endocapillary proliferation on renal biopsy is more likely a manifestation of SLE than the coexistence of idiopathic minimal-change glomerulopathy and SLE.

Citing Articles

Clinical presentation, outcomes and risk of relapses of lupus podocytopathy in a multicentre Italian cohort.

Bonelli G, Sciascia S, Calatroni M, LImperio V, Fenoglio R, Argolini L J Nephrol. 2025; .

PMID: 39883361 DOI: 10.1007/s40620-024-02178-1.


The Role of Podocytes in Lupus Pathology.

Maeda K, Abdi R, Tsokos G Curr Rheumatol Rep. 2024; 27(1):10.

PMID: 39731699 DOI: 10.1007/s11926-024-01175-4.


An Unusual Case of Nephrotic Range Proteinuria in a Short-Standing Type 1 Diabetic Patient with Newly Diagnosed Systemic Lupus Erythematosus: A Case Report and Literature Review.

Dominguez Davalos M, De La Flor J, Bedia Castillo C, Lipa Chancolla R, Rodriguez Tudero C, Apaza J Med Sci (Basel). 2024; 12(4).

PMID: 39728423 PMC: 11677153. DOI: 10.3390/medsci12040074.


Evidence based treatment for lupus nephritis: present perspectives and challenges.

Xagas E, Drouzas K, Liapis G, Lionaki S Front Nephrol. 2024; 4:1417026.

PMID: 39165275 PMC: 11333434. DOI: 10.3389/fneph.2024.1417026.


Risk factors for acute kidney injury and kidney relapse in patients with lupus podocytopathy.

Xia W, Deng J, Zhuang L, Xu F, Jin Y, Zhou H Clin Kidney J. 2024; 17(6):sfae148.

PMID: 38835511 PMC: 11145460. DOI: 10.1093/ckj/sfae148.